Q-omics provides the consensus-scored JHY profile across patient tissues and cancer cell-line models. JHY expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, JHY is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, JHY RNA expression shows 19,711 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, KICH, and THYM as cancer lineages where JHY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JHY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JHY survival associations across molecular data types. JHY RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JHY RNA expression–survival associations across cancer types. High JHY expression shows unfavorable associations in LUSC, MESO, LGG and STAD, but favorable associations in KIRC and UCEC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for JHY RNA expression.
This table summarizes JHY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for JHY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JHY shows lower tumor expression in KICH, KIRP, KIRC, THCA and LUSC and higher tumor expression in HNSC. The KICH box plot shows higher JHY RNA expression in normal versus tumor tissue (log2 FC = −2.449, t-test p < 0.001).
This table shows molecular features associated with JHY in patient tissues and cancer cell lines. In patient samples, JHY shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, JHY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
